tbuckley/cabot-search huggingface dataset:
P1.07-052 Pulmonary Neuroendocrine Tumors: Single Institution Experience in Brazil
Authors: Renata Rosenthal, Maria Teresa Tsukazan, Álvaro Vigo, Flávio Cabral, Arthur Vieira, Gabriel Schwarcke, Jayme Rios, José Antonio Pinto, Vinícius Duval Da Silva
Journal: Journal of Thoracic Oncology (2017)
Rapid Response of Biallelic BRAF V600E Hairy Cell Leukaemia to Low Dose Vemurafenib
Authors: Hannah Sims, David Bloxham, Hannah Creasey, Elaine Bradford, Hongxiang Liu, Penny Wright, Anthony Bench, Melanie A Hopper, Mars van't Veer, Charles Crawley, Mike Scott, George Follows
Journal: Blood (2012)
P99 Cystic fibrosis medications at transfer from paediatric to adult care – what are patients actually taking?
Authors: J Strange, K Cox, A Jones
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Cystic fibrosis (CF) is a multi-system disease requiring complex, high-burden treatment regimens. Discrepancies can arise between hospital and GP drug lists, in turn impacting patient’s access to required long-term medications. One large adult CF centre has been conducting medicines reconciliation at the point of transition from paediatric care, with the goal of identifying and eliminating such discrepancies. The objective of this study was to evaluate the accuracy of hospital medication lists versus the GP repeat prescription lists, at the point of transition from paediatric to adult care. <h3>Methods</h3> Drug lists were assessed for discrepancies, in drug or dose, as well as non-collection of items. These issues were sub-grouped to evaluate whether frequency varied by drug class. <h3>Results</h3> Drug list from 99 patients from a 4.5-year period (2011–2016) were included, featuring a total of 1201 items, with a mean of 12, range 1–22, items per patient. There was a drug discrepancy in 11.7% of total items, with greatest frequency occurring in inhaled and nebulised antibiotics (20.0%), as seen in Figure 1. There was a dose discrepancy in 3.9% of total items, with greatest frequency occurring in oral antibiotics (8.7%). It was also found that 9.2% of items had not been collected from GP for ≥6 months, with greatest frequency occurring in nebulised medicines 13.8%. <h3>Conclusions</h3> Discrepancies are common across CF medication lists. These may have a detrimental impact on clinical care, as patients are unable to access the required medicines from their GP, and hospitals may prematurely escalate care. Furthermore, a number of items prescribed by GPs are not regularly collected, indicating poor adherence. Medicines reconciliation at transition of care has a significant impact in identifying these issues, and CF centres should consider whether to also routinely include this process during CF annual reviews.
P1.07-054 Second Primary Small Cell Carcinoma of Lung in Previously Treated Carcinoma Breast
Authors: Prasanta Mohapatra, Pritinanda Mishra, Manoj Panigrahi, Gourahari Pradhan, Sourin Bhuniya, Susama Patra, Madhabananda Kar
Journal: Journal of Thoracic Oncology (2017)
Thromboelastography - Viscoelastic Haemostatic Assay (VHA) Versus Routine Plasma Based Coagulation Parameters in Trauma Patients to Detect Coagulopathy within 24 Hrs After Injury
Authors: Bhaumik Arvindkumar Shah, Arulselvi Subramanium, Subhadra Sharma, Deepak Agrawal, Gaurav Chhabra, Asok Kumar Mukhopadhyay
Journal: Blood (2011)
α<sub>1</sub>-Antitrypsin deficiency: count me in please!
Authors: Joan B. Soriano, Ravi Mahadeva
Journal: European Respiratory Journal (2017)

Respiratory medicine is facing formidable challenges in the 21st century. Indeed, most respiratory medical research is becoming interconnected, translational and transnational, all embedded within so-called "planetary health" [1]. However, renewing estimates and trends from classical, descriptive epidemiology, including how many patients of a given condition are around, and how many are expected in the future, remain ongoing chores. Continuous updates from the World Health Organization's Global Burden of Disease initiative reiterate that respiratory diseases rank high in morbidity and mortality, even with widespread underdiagnosis [2]. Perhaps there is no better example of a respiratory condition that requires further epidemiological and population refreshing than severe α1-antitrypsin deficiency (AATD). Severe AATD is considered a rare disease, which is defined as any disease that affects less than 1 in 2000 individuals [3]. The prevalence of AATD in the general population in Europe is approximately 1 in 2000–5000. Knowing the number of AATD patients is a first step to tackling the AATD problem <http://ow.ly/JNPJ305OopX>
P2.05-021 Stereotactic Radiosurgery for Brain Metastasis in Non-Small Cell Lung Cancer: Predictor of Intracranial Progression
Authors: Yeon Sil Kim, Yong Kyun Won, Jin Hyoung Kang, Seung Joon Kim, So-Lyoung Jung, Sook Hee Hong
Journal: Journal of Thoracic Oncology (2017)
ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative
Authors: Jason E. Farrar, Todd A. Alonzo, Rhonda E. Ries, Robert B. Gerbing, Jaime M. Guidry Auvil, Tanja M. Davidsen, Patee Gesuwan, Leandro C. Hermida, Marco A Marra, Andrew J. Mungall, Karen Mungall, Yussanne Ma, William Long, Stuart Zong, E. Anders Kolb, Malcolm A. Smith, Daniela S. Gerhard, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2015)
Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for High Risk Acute Pediatric Leukemia. Promising Results Using a Protocol with Peripheral Blood and a Medium Intensity Conditioning
Authors: Amado J Karduss-Urueta, Suarez Gloria, Gonzalez Miguel, Perez Rosendo, Pedro Reyes, Alejo Jimenez, Luis R Gomez, Angelica M Cardona, Jose Betancur, Monica Ramirez, Giovanni Ruiz
Journal: Blood (2015)
Telomere Attrition and Chromosomal Instability During Long-Term Cultivation of Hematopoietic Stem Cells,
Authors: Kathrin Lange, Beate Kuhlmann, Andrea Schienke, Axel Schambach, Ute Modlich, Christopher Baum, Brigitte Schlegelberger, Gudrun Göhring
Journal: Blood (2011)
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Authors: Andreas Geier, Carsten Gartung, Christoph G Dietrich
Journal: New England Journal of Medicine (2002)

BackgroundThe presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes.HBeAg is thus a surrogate marker for the presence of hepatitis B virus DNA.We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma.Methods In 1991 and 1992, we enrolled 11,893 men without evidence of hepatocellular carcinoma (age range, 30 to 65 years) from seven townships in Taiwan.Serum samples obtained at the time of enrollment were tested for HBsAg and HBeAg by radioimmunoassay.The diagnosis of hepatocellular carcinoma was ascertained through data linkage with the computerized National Cancer Registry in Taiwan and with death certificates.We performed a multiple regression analysis to determine the relative risk of hepatocellular carcinoma among men who were positive for HBsAg alone or for HBsAg and HBeAg, as compared with those who were negative for both. ResultsThere were 111 cases of newly diagnosed hepatocellular carcinoma during 92,359 person-years of follow-up.The incidence rate of hepatocellular carcinoma was 1169 cases per 100,000 person-years among men who were positive for both HBsAg and HBeAg, 324 per 100,000 person-years for those who were positive for HBsAg only, and 39 per 100,000 person-years for those who were negative for both.After adjustment for age, sex, the presence or absence of antibodies against hepatitis C virus, cigarette-smoking status, and use or nonuse of alcohol, the relative risk of hepatocellular carcinoma was 9.6 (95 percent confidence interval, 6.0 to 15.2) among men who were positive for HBsAg alone and 60.2 (95 percent confidence interval, 35.5 to 102.1) among those who were positive for both HBsAg and HBeAg, as compared with men who were negative for both.Conclusions Positivity for HBeAg is associated with an increased risk of hepatocellular carcinoma.
P3.02c-103 Effect of Anti-PD-1 Therapy on Immune Cells in the Peripheral Blood of Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: Eleni- Kyriaki Vetsika, Despoina Aggouraki, Zacharoula Lyristi, Filippos Koinis, Vassilis Georgoulias, Athanasios Kotsakis
Journal: Journal of Thoracic Oncology (2017)
Is It Better to Treat Adolescents with Acute Lymphoblastic Leukemia as Old Children or as Young Adults?
Authors: Marta Alves, Liane Daudt, Karina L. M. Mazzucco, Adriano Taniguchi, Tiago Nava, Fabio L. Moreno, Alice Gonzalez, Lucia Silla
Journal: Blood (2008)
Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.
Authors: Corey Cutler, David Miklos, Stephanie J. Lee, Sook-Bin Woo, Nathaniel Treister, Don Bienfang, Lloyd Klickstein, Jesse Levin, Katherine H. Miller, Carol Reynolds, Mildred Pasek, Vincent Ho, Jerome Ritz, Joseph H. Antin, Robert Soiffer, Edwin Alyea
Journal: Blood (2004)
P1.08-084 Treatment for Elderly Patients with Clinical Stage I Non-Small Cell Lung Cancer; Surgery or Stereotactic Body Radiotherapy?
Authors: Takuro Miyazaki, Takuya Yamazaki, Daisuke Nakamura, Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro Matsumoto, Ryotaro Kamohara, Go Hatachi, Takeshi Nagayasu
Journal: Journal of Thoracic Oncology (2017)
A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia
Authors: Suporn Chuncharunee, Raymond SM Wong, Ponlapat Rojnuckarin, Cheng-Shyong Chang, Kian Meng Chang, Meng-Yao Lu, Wen-Li Hwang, Liang Piu Koh, Tsai-Yun Chen, Anskar YH Leung, Lalita Norasetthada, Shih-Chung Wang, Ming-Chih Chang, Kang-Hsi Wu, Surapol Issaragrisil
Journal: Blood (2015)
P2.01-047 Intra- and Inter-Observer Reproducibility Study of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC) - The DREAM STUDY
Authors: Wendy Cooper, Prudence Russell, Phillipe Huot-Marchand, Maya Cherian, Edwina Duhig, David Godbolt, Peter Jessup, Christine Khoo, Connull Leslie, Annabelle Mahar, David Moffat, Vanathi Sivasubramaniam, Amanda Grattan, Alena Reznichenko, Ann-Marie Woodgate, Sephen Fox
Journal: Journal of Thoracic Oncology (2017)
Utility and costs of surrogate endpoints (SEs) and biomarkers in phase I oncology trials
Authors: B. H. L. Goulart, T. G. Roberts, J. W. Clark
Journal: Journal of Clinical Oncology (2004)

6012 Background: The advent of targeted therapies, functional imaging and translational research has driven the use of a new class of endpoints in phase I oncology trials, known as surrogate endpoints (SEs) or biomarkers. Investigators hope that SEs will improve the efficiency of drug-development. However, whether SEs can substitute for traditional endpoints (e.g. toxicity) is unknown. The role of SEs in drug selection, target validation, dosing and schedule optimization remains to be defined. Methods: We analyzed all phase I single-agent studies in PASCO from 1992 to 2002 that included at least one SE. Subsequent publications of these studies were analyzed with respect to the primary SE. Drugs were classified as cytotoxic, biologic (recombinant), or targeted (small molecules) and SEs classified by their technology (imaging, blood biomarkers or advanced histology). We designed 4 yes-no questions to evaluate the role of SEs, beginning with: “Did the SE help…” 1) “…determine the dose for phase II?”; 2) “…in finding the schedule?”; 3) “… with the author's conclusions?”; and 4) “… validate that the target was affected?”. The utility of SEs across these questions and across drug classes was compared by McNemar's and chi-square tests, respectively. We also related the budgets of 18 single-institutional trials to their number of endpoints. Results: Of 65 trials, 55% tested biologics, 24% small molecules, 15% cytotoxic and 6% other. The percentages of primary SE's by technology were: 68% blood studies, 25% histologic analysis, and 6% imaging. The frequency of “yes” for the 4 questions was 14%, 15%, 34% and 62%, respectively (p<0.001 between questions), with no statistical differences between drug classes. The marginal budgeted cost of adding an additional secondary endpoint was US$6,675 per patient. Conclusions: SEs differ in methods and goals. SEs only modestly aided in defining dose and schedule for future studies and in the overall drug-development process. They helped in validating that the therapy affected the intended target. Better preclinical evaluation of SEs may enhance their utility. Further research should help define how best to incorporate SE's into trial design. No significant financial relationships to disclose.
P170 Single centre experience on idiopathic pulmonary fibrosis patient tolerance of pirfenidone; impact on nurse-led ILD helpline usage
Authors: A Rathnapala, C Ruggiero, A Fries, LP Ho, RK Hoyles
Journal: Thorax (2016)

<h3>Introduction</h3> Idiopathic pulmonary fibrosis (IPF) is a progressively scarring lung disease with a poor prognosis. The anti-fibrotic agent Pirfenidone slows FVC decline and reduces mortality. Side-effect management is critical to help patients remain on treatment. <h3>Objectives</h3> To examine tolerance to Pirfenidone in our specialist ILD centre: to identify the prevalence, nature and management of adverse effects, and the impact on the ILD nurse-led helpline. <h3>Methods</h3> In this retrospective study, all patients with an ILD MDT diagnosis (ATS/ERS) of IPF treated with Pirfenidone for &gt;3 months were included. Data was derived from the patient records and nurse-led ILD helpline logs. <h3>Results</h3> 100 patients were treated with Pirfenidone Feb 2012–July 2016. 16 patients were excluded (&lt;3 months’ treatment (n = 7), death &lt;1 month (n = 2), other (n = 7), 84 remained in the study; Definite: Probable IPF 47:37, male: female 68:16, average age 73.7 (40–88). 72 (85.7%) experienced at least one adverse effect; appetite/weight loss (n = 39, 34.5%), nausea (n = 26, 23%), diarrhoea (n = 17, 15%), fatigue (n = 11, 9.7%), photosensitivity (n = 11, 9.7%), skin rash (n = 9, 8%). No patients required side-effect-related hospital admission. Management: treatment pause (n = 36, 50%), dose reduction alone (n = 15, 20.8%), initial reduction and subsequent pause (n = 4, 5.6%). n = 17 (23.6%) with mild side-effects were managed with advice alone (dose unchanged). Of those with dose reductions/pause (n = 55), 21 (38%) were gradually re-escalated to full dose, 1 (2%) continued on reduced dose. Pirfenidone was discontinued and offered symptom-based management in n = 17 (31%), (unable to switch to Nintedanib due to FVC &lt; 50% (7), not preferred (3), bleeding risk (2), other (5)), while n = 16 (29%) were able to switch to Nintedanib. Impact on the nurse-led helpline was assessed in n = 45 (unselected subset); &gt; 82% used the helpline, often initiated due to side-effects; patients with deteriorating symptoms or end-stage disease engaged most frequently. <h3>Conclusions</h3> In this real-life study, we found a higher prevalence of side effects than previously described. Nurse-led helpline use was often initiated by side effect concerns, but usage broadened into more holistic support as the nurse patient relationship developed. In response, the Oxford ILD Service has initiated a side-effect management protocol with more cautious (than standard) initial escalation and re-challenging regime.
Ex-Vivo Generation and Expansion of Both Lymphoid and Myeloid Lineages from Human Cord Blood (CB) HSC Using a Serum-Free Human Mesenchymal Stem Cell Based Culture System.
Authors: Ana Frias, Christopher D. Porada, Kirsten B. Crapnell, Joaquim M.S. Cabral, Esmail D. Zanjani, Graca Almeida-Porada
Journal: Blood (2004)
One Year Reinductions with Vincristine, Asparaginase and Prednisone as Post-Remission Therapy Improves Outcome in Children with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL).
Authors: Albert Oriol, Pilar Bastida, Olga García, Carlota Calvo, Juan-Manuel Perez-Hurtado, Maria-Elvira González Valentin, Jose Luis Fuster, Izaskun Egurbide, Victoria Martin-Reina, Antonio Molines, Javier Lassaletta, Miguel-Angel Sanz, Mar Tormo, Mercedes Carnero, Juan-José Ortega, Josep-Maria Ribera
Journal: Blood (2009)
Reduction in adolescent depression after contact with mental health services: a longitudinal cohort study in the UK
Authors: Sharon A S Neufeld, Valerie J Dunn, Peter B Jones, Tim J Croudace, Ian M Goodyer
Journal: The Lancet Psychiatry (2017)

Evidence regarding the association between service contact and subsequent mental health in adolescents is scarce, and previous findings are mixed. We aimed to longitudinally assess the extent to which depressive symptoms in adolescents change after contact with mental health services.As part of a longitudinal cohort study, between April 28, 2005, and March 17, 2010, we recruited 1238 14-year-old adolescents and their primary caregivers from 18 secondary schools in Cambridgeshire, UK. Participants underwent follow-up assessment at months 18 and 36. Trained researchers assessed the adolescents for current mental disorder using the Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime version (K-SADS-PL). Caregivers and adolescents reported contact with mental health services in the year before baseline. Adolescents self-reported depressive symptoms (Mood and Feelings Questionnaire [MFQ]) at each timepoint. We assessed change in MFQ sum scores from baseline contact with mental health services using multilevel mixed-effects regression adjusted for sociodemographic, environmental, individual, and mental health confounders, with multiple imputation of missing data. We used propensity score weighting to balance confounders between treatment (users of mental health services) and control (non-users of mental health services) groups. We implemented an MFQ clinical cutoff following the results of receiver operating characteristic analysis.14-year-old adolescents who had contact with mental health services in the past year had a greater decrease in depressive symptoms than those without contact (adjusted coefficient -1·68, 95% CI -3·22 to -0·14; p=0·033). By age 17 years, the odds of reporting clinical depression were more than seven times higher in individuals without contact than in service users who had been similarly depressed at baseline (adjusted odds ratio 7·38, 1·73-31·50; p=0·0069).Our findings show that contact with mental health services at age 14 years by adolescents with a mental disorder reduced the likelihood of depression by age 17 years. This finding supports the improvement of access to adolescent mental health services.Wellcome Trust, National Institute for Health Research.
P3.07-001 Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing
Authors: Klazien Matter-Walstra, Matthias Schwenkglenks, Stefan Aebi, Konstantin Dedes, Joachim Diebold, Mario Pietrini, Dirk Klingbiel, Roger Von Moos, Oliver Gautschi
Journal: Journal of Thoracic Oncology (2017)
5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)
Authors: Naval Daver, Guillermo Garcia-Manero, Jorge E. Cortes, Lingsha Zhou, Sherry Pierce, Naveen Pemmaraju, Elias Jabbour, Courtney DiNardo, Tapan Kadia, Gautam Borthakur, Farhad Ravandi, Marina Konopleva, Franklin Wynn, Stephanie Van Derbur, Zeev Estrov, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Blood (2015)
OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)
Authors: David Spigel, M Catherine Pietanza, Todd Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren Averett Byers, Melissa Johnson, Howard Burris, Francisco Robert, Tae Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Donald Strickland, Hany Zayed, Scott Dylla, Stanford Peng, Ramaswamy Govindan, Charles Rudin
Journal: Journal of Thoracic Oncology (2017)
Abstract C52: Collagen-mediated chromatin remodeling promotes chemoresistance in pancreatic cancer
Authors: Surabhi Y. Danqi-Garimella, Hidayatullah G. Munshi
Journal: Cancer Research (2011)

Abstract Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related deaths in the U.S., is associated with a pronounced collagenrich stromal reaction that has been shown to contribute to chemoresistance. We recently published that PDAC cells grown in the collagen microenvironment are resistant to gemcitabine-induced proliferation and checkpoint arrest (Dangi-Garimella et al, Cancer Research 2011). The effects were mediated through upregulation of membrane type 1-matrix metalloproteinase (MT1-MMP)- and ERK1/2-dependent expression of high mobility group A2 (HMGA2), a well-known chromatin remodeling protein. We have now found that relative to cells grown on tissue culture plastic, PDAC cells grown in 3-D collagen display increased acetylation of lysines K9 and K27 on histone H3 along with a reduction in the levels of the heterochromatin binding protein HP1-α, suggesting that cells in collagen have a more open chromatin state. Decreasing MT1-MMP or HMGA2 expression or inhibiting ERK1/2 activity attenuates the effect of collagen on K9 and K27 acetylation. Collagen also increases Aurora kinase B-dependent phosphorylation of S10 on histone H3, which has been shown to reduce HP1-α binding to the chromatin and thereby promote more open chromatin state. 3-D collagen also increases expression of the histone acetyl transferase enzymes pCAF and GCN5. Finally, cells in 3D matrix demonstrate increased H2AX and a reduced tailing with the comet assay following gemcitabine treatment, suggesting that there is increased DNA repair associated with the more open chromatin state when cells are in the 3-D collagen microenvironment. Overall, our results increase our understanding of how growth in 3-D collagen contributes to chemoresistance and identify potential therapeutic targets against this deadly cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C52.